Our seasoned board of directors helps guide the company in leading the way to bringing forward innovative medicines for multiple forms of dementia and other neurologic disorders.

Vivek Ramaswamy

Mr. Ramaswamy is founder and Chief Executive Officer of Roivant Sciences, Inc., and founder and former Chief Executive Officer of Axovant Sciences, Inc. Prior to founding Roivant, Mr. Ramaswamy was a well-known investor in the biotechnology sector. In 2007, he cofounded and served as President of Campus Venture Network, a technology company that was acquired in 2009. He currently serves as Chairman of the board of directors of Arbutus Biopharma Corporation and is director of Axovant Sciences Ltd., Myovant Sciences Ltd., and Roivant Sciences Ltd.

Mr. Ramaswamy received an A.B. in biology from Harvard College and a J.D. from Yale Law School.

Atul Pande, M.D.

Dr. Pande has served as a member of the board since March 2015. He serves as the Chief Medical Officer of PureTech Health. Since April 2014, Dr. Pande has served as President of Verity BioConsulting, a drug development consulting firm, and since December 2014 has served as Chief Medical Officer of Tal Medical, a clinical-stage medical device company. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D, at GlaxoSmithKline. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. Dr. Pande is also a non-executive board member of Autifony Therapeutics and  Karuna Pharmaceuticals. He serves on the scientific advisory boards of Cennerv Pharma and Centrexion Corporation.

Dr. Pande received an MBBS (Bachelor of Medicine, Bachelor of Surgery) from the University of Lucknow, India, and completed his research fellowship training in psychiatry at the University of Michigan Medical School and postgraduate specialty training and psychiatry residency program at Western University.

Ilan Oren

Mr. Oren has served as a member of the board since March 2015. He has served as Vice President, Business Development, at Dexcel Pharma Technologies Ltd., an international pharmaceutical company involved in the development, manufacture, and commercialization of pharmaceuticals since September 2011. From 2007 to July 2011, he was employed by L.E.K. Consulting and advised clients in the life sciences sector on corporate strategy, mergers and acquisitions, licensing, and drug commercialization projects. Mr. Oren currently serves as a director of Cynapsus Therapeutics Inc., a publicly traded specialty pharmaceutical company, and as a director of Roivant Sciences Ltd.

Mr. Oren received a B.A. in economics from Harvard College.

Berndt Modig

Mr. Modig has served as a member of the board since March 2015. Since March 2016, Mr. Modig has served as Chief Executive Officer of Pharvaris B.V. He served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008, Mr. Modig was Chief Financial Officer at Jerini AG, a pharmaceutical company, where he directed private financing rounds, its initial public offering in 2005, and its acquisition by Shire plc in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a Partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director and member of the Audit Committee of Affimed N.V., and as a director and chair of the Audit Committee of Auris Medical Holding AG, both publicly held pharmaceutical companies. He also serves on the supervisory board of Kiadis Pharma N.V., and was a director of Mobile Loyalty plc from 2012 to 2013.

Mr. Modig received a bachelor’s degree in business administration, economics and German from the University of Lund, Sweden, and an M.B.A. from INSEAD, Fontainebleau, France. He is a certified public accountant (inactive).

David T. Hung, MD

Dr. Hung has served as Chief Executive Officer of Axovant Sciences, Inc. and a member of the board since April 2017. Previously, he was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors until its acquisition by Pfizer Inc. Before that, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer and then as President and Chief Executive Officer. He has also served as a consultant to Cytyc Corporation to assist with transitional matters related to its acquisition of ProDuct Health, Inc. and has served as a member of the board of directors of Opexa Therapeutics, Inc., a biopharmaceutical company. Dr. Hung received an MD from the University of California, San Francisco, School of Medicine, and an AB in biology from Harvard College.

Kathryn Falberg

Ms. Falberg has served as a member of the board since April 2017. Previously, she served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a multinational specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications, and information technology. From 2001 through 2009, Ms. Falberg served as a corporate director and Audit Committee chair for several companies. From 1995 to 2001, Ms. Falberg was with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Finance and Strategy, and Chief Financial Officer; and prior to that she was Vice President, Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg also serves as a member of the board of directors for the public biopharmaceutical companies Aimmune Therapeutics, Inc., aTyr Pharma, Inc., and BioMarin Pharmaceutical Inc., and The Trade Desk, Inc., a publicly held technology company. Ms. Falberg served on the board of directors of public companies Medivation, Inc., and Halozyme Therapeutics, Inc.

Ms. Falberg received an M.B.A. in finance and a B.A. in economics from the University of California, Los Angeles. She is a certified public accountant (inactive).

Tony Vernon

Mr. Vernon has served as a member of the board since April 2017. Previously, he served as senior advisor to Kraft Foods Group, Inc., from January 2015 through May 2015, and Chief Executive Officer for Kraft Foods Group, Inc., from October 2012 to December 2014. Mr. Vernon previously served as Executive Vice President and President at Kraft Foods of North America from 2009 to October 2012. From 2006 to 2009, he was the Healthcare Industry Partner at Ripplewood Holdings, Inc., a private equity firm. Mr. Vernon previously led a number of Johnson & Johnson’s largest franchises during a 24-year career at the company. From 2004 until 2005, Mr. Vernon was employed as Company Group Chairman of DePuy Inc., a subsidiary of Johnson & Johnson. From 2001 until 2004, he served as President and Chief Executive Officer of Centocor, Inc., a division of Johnson & Johnson. He served as President of McNeil Consumer Products and Nutritionals, Worldwide President of The Johnson & Johnson-Merck Joint Venture, and as a member of Johnson & Johnson’s Group Operating Committees for Consumer Healthcare and Nutritionals, Biopharmaceuticals, and Medical Devices and Diagnostics. Mr. Vernon serves as a member of the board of directors of medical device companies NovoCure Ltd. and Intersect ENT, Inc., and The WhiteWave Foods Company, a consumer packaged food and beverage company. He formerly served as a director of Medivation, Inc., and Kraft Foods Group, Inc.

Mr. Vernon received a B.A. in history from Lawrence University and an M.B.A. from the Northwestern University Kellogg Graduate School of Management.

Patrick Machado

Mr. Machado has served as a member of the board since June 2017. Previously, he was a co-founder of Medivation, Inc., and served as its Chief Financial Officer from 2004 to 2014, as well as its Chief Business Officer from 2009 to 2014. He also served as a director of Medivation from April 2014 until its acquisition by Pfizer Inc. in September 2016. From 1998 until 2001, Mr. Machado worked with ProDuct Health, Inc., a privately held medical device company, as Senior Vice President, Chief Financial Officer, and earlier as General Counsel. Mr. Machado served as a consultant to Cytyc Corporation from 2001 until 2002 to assist with transitional matters related to its acquisition of ProDuct Health, Inc. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court.

Mr. Machado received a J.D. from Harvard Law School, and a B.A. in German and a B.S. in economics from Santa Clara University.